Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization

by B2i | Mar 11, 2024 | Press Releases

JUNIPER, Fla., March 11, 2024 — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for...

Dyadic to Attend Industry Events in March

by B2i | Mar 1, 2024 | Press Releases

JUPITER, Fla. , March 01, 2024 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

by B2i | Feb 28, 2024 | Press Releases

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying...

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

by B2i | Feb 21, 2024 | Press Releases

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 — Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and...

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

by B2i | Feb 13, 2024 | Press Releases

JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 — Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic...